Becton Dickinson and (BDX) Receiving Somewhat Favorable News Coverage, Analysis Shows

Media stories about Becton Dickinson and (NYSE:BDX) have trended somewhat positive recently, according to Alpha One Sentiment Analysis. The research firm, a unit of Accern, identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Becton Dickinson and earned a news sentiment score of 0.08 on Alpha One’s scale. Alpha One also gave news coverage about the medical instruments supplier an impact score of 42 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

These are some of the news articles that may have effected Alpha One’s analysis:

A number of equities analysts recently weighed in on the company. Zacks Investment Research lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Evercore ISI upgraded Becton Dickinson and from an “in-line” rating to an “outperform” rating and increased their price target for the company from $186.00 to $200.00 in a research report on Monday, April 24th. Royal Bank of Canada reiterated a “hold” rating and issued a $177.00 price target on shares of Becton Dickinson and in a research report on Thursday, April 13th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $200.00 price target on shares of Becton Dickinson and in a research report on Wednesday, March 29th. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. Becton Dickinson and has a consensus rating of “Buy” and a consensus target price of $186.09.

Shares of Becton Dickinson and (NYSE:BDX) opened at 184.13 on Friday. The firm’s 50-day moving average price is $183.37 and its 200-day moving average price is $176.79. The firm has a market capitalization of $39.28 billion, a price-to-earnings ratio of 30.58 and a beta of 1.00. Becton Dickinson and has a 12 month low of $161.29 and a 12 month high of $187.69.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, May 2nd. The medical instruments supplier reported $2.30 EPS for the quarter, beating analysts’ consensus estimates of $2.23 by $0.07. Becton Dickinson and had a return on equity of 25.25% and a net margin of 10.54%. The business had revenue of $2.97 billion during the quarter, compared to analyst estimates of $2.92 billion. During the same period in the previous year, the company posted $2.18 EPS. The firm’s revenue was down 3.2% compared to the same quarter last year. On average, equities analysts anticipate that Becton Dickinson and will post $9.44 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another site, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this news story can be read at https://sportsperspectives.com/2017/05/20/becton-dickinson-and-bdx-given-media-impact-score-of-0-08-updated-updated.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

12 Month Chart for NYSE:BDX

Receive News & Ratings for Becton Dickinson and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply